Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics (NYSE: DGX) has announced the launch of a new diagnostic laboratory test for the Oropouche virus, an emerging infectious disease prevalent in South and Central America and the Caribbean. The test, developed at Quest's San Juan Capistrano laboratory, will be available with a prescription by the end of July 2025.

The diagnostic solution employs PCR technology for early-stage detection, with serology testing planned for later in the quarter. This development follows Quest's CDC contracts awarded in September 2024 to support testing readiness for emerging infectious diseases. The initiative demonstrates Quest's role in preparing the U.S. healthcare system for potential public health threats.

[ "Development of first commercial diagnostic test for Oropouche virus in response to CDC contract", "Expansion of testing capabilities with both PCR and upcoming serology testing options", "Strategic positioning for potential public health threats through CDC contract funding" ]

Quest Diagnostics (NYSE: DGX) announced plans to offer the first FDA-cleared blood-based test for Alzheimer's disease, the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test from Fujirebio. The test will be available for clinical and research use starting summer 2025.

The FDA-cleared test demonstrated impressive clinical results with a 92% positive predictive value and 97% negative predictive value in a study of 499 patients. It's designed for adults aged 50+ showing signs of cognitive decline in specialized care settings. Quest will provide the test through its network of approximately 8,000 patient access points, including 2,000 patient service centers across the U.S.

This addition complements Quest's existing AD-Detect™ portfolio of blood tests for Alzheimer's assessment, offering a less invasive and more convenient alternative to traditional amyloid PET imaging and spinal fluid testing methods.

Quest Diagnostics (NYSE: DGX) has released its 2024 Corporate Responsibility Report titled "Care Starts Here," highlighting the company's achievements across four strategic pillars: health access, employee and community engagement, governance and ethics, and environmental sustainability.

Key accomplishments in 2024 include: $13 million in corporate giving and Foundation grants, support for nearly 40 programs through the Quest Diagnostics Foundation, provision of one million donated or discounted test requisitions, and introduction of 50 new testing services. The company also spent $300 million with small U.S. businesses and welcomed Robert Carter, former FedEx CIO, to its board of directors.

Environmental initiatives included reducing electricity and single-use plastics usage, transitioning to electric and hybrid vehicles, and pursuing ISO 14001-2015 certification for additional facilities.

Quest Diagnostics (NYSE: DGX), a leading diagnostic information services provider, has scheduled the release of its Q2 2025 financial results for July 22, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the results. Participants can join via phone using specific dial-in numbers for U.S./Canada (888-455-0391) and international callers (773-756-0467) with passcode "7895081". The earnings release and webcast will be available on Quest's investor website. A replay will be accessible until August 5, 2025, through the website or dedicated phone numbers. The company recommends reviewing their SEC periodic reports for risk factors and historical financial information.

Quest Diagnostics (NYSE: DGX) has announced a collaboration with MD Anderson Cancer Center to develop a novel Multi-cancer Stratification Test (MCaST) blood test. The test will assess elevated risk for multiple cancers including colorectal, lung, breast, pancreatic, ovarian, liver, prostate, esophageal and stomach cancers. Based on technology developed by Dr. Samir Hanash's team at MD Anderson, the test uses circulating protein biomarkers and was validated through extensive clinical research involving tens of thousands of individuals. Quest plans to commercialize the test in North America by 2026, positioning it as a supplement to conventional screening methods. The test aims to provide a more accessible, affordable alternative to current screening methods, addressing the concerning statistic that only 51% of U.S. adults undergo routine medical appointments or cancer screenings annually.

Quest Diagnostics' second "Know Your Health" survey reveals concerning gaps in Americans' health awareness. The survey of 2,100 U.S. adults found that 40% know their streaming passwords by heart, while only 19% know their cholesterol scores. While 92% of Americans actively prepare for future health needs, many face barriers to healthcare access. Notably, 37% reported obstacles in receiving medical care, with higher percentages among younger generations. The survey highlighted that 30% of Americans feel their healthcare providers don't adequately discuss prevention and wellness. Despite these challenges, 70% of Americans rate their health as good or excellent, with sleep (71%), hydration (65%), and exercise (62%) being top health priorities. The study also revealed that 63% of Americans are unaware they can purchase lab tests without a doctor's visit, highlighting opportunities for Quest's consumer-initiated testing platform.

Quest Diagnostics (NYSE: DGX) announced that Chairman, CEO and President Jim Davis will deliver a presentation at the William Blair 45th Annual Growth Stock Conference in Chicago. The presentation is scheduled for June 3, 2025, at 11:00 a.m. Eastern Time.

During the presentation, Davis will discuss the company's strategy, performance, and current market trends. Investors can access the live webcast through Quest's investor relations page at ir.QuestDiagnostics.com. The archived version will be available within 24 hours after the event and remain accessible until July 3, 2025.

[]

Quest Diagnostics (NYSE: DGX), a leading diagnostic information services provider, has announced a quarterly cash dividend of $0.80 per share. The dividend will be paid on July 21, 2025, to shareholders who are on record as of July 7, 2025. This regular dividend declaration demonstrates Quest's commitment to providing consistent returns to its shareholders.

A new Quest Diagnostics (DGX) report reveals concerning trends in cancer care, with 76% of oncologists reporting increased advanced cancer cases. Among these, 75% attribute this rise to screening barriers. The report highlights significant challenges in detecting cancer recurrence, with 79% of oncologists encountering cases where recurrence was missed in earlier stages. Key findings show that 68% of cases were missed due to delayed follow-up care, while 50% cite limitations in current imaging tests. The study emphasizes the potential of circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing, with 94% of oncologists believing it could reduce diagnosis delays. Quest's Haystack MRD™ test has shown promising results, detecting treatment response 1.4 months faster than traditional methods. However, broader adoption faces barriers including insurance coverage and the need for more clinical evidence.